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Reactive oxygen speciesAngiopoietin-1 (Ang1) is a ligand for the receptor tyrosine kinase Tie2 and has key roles in the development of
the vascular system and vascular protection. In a screen to deﬁne signalling pathways regulated by Ang1 in en-
dothelial cells we found the RNA-binding protein hnRNP-K to be phosphorylated in response to Ang1. The ligand
stimulated both tyrosine phosphorylation of hnRNP-K and recruitment of the tyrosine kinase Src to the RNA-
binding protein. In endothelial cells hnRNP-K was found bound to mRNA encoding the mitochondrial protein
uncoupling protein-2 (UCP2). Ang1 stimulation of cells resulted in the release of UCP2 mRNA from hnRNP-K.
Using in vitro assays we conﬁrmed direct binding between hnRNP-K and UCP2 mRNA. Furthermore Src induced
phosphorylation of puriﬁed hnRNP-K and prevented UCP2 mRNA binding. Tyrosine 458 in the RNA-binding
protein was found to be required for suppression of UCP2 mRNA binding by Src phosphorylation. In addition
to releasing UCP2 mRNA from hnRNP-K, Ang1 induced an increase in UCP2 protein expression in endothelial
cells without affecting total UCP2mRNA levels. Consistentwith the known effects of UCP2 to suppress generation
of reactive oxygen species, Ang1 limited ROS production in endothelium stimulatedwith tumour necrosis factor-α.
Taken together these data suggest that UCP2mRNA is present in endothelial cells bound to hnRNP-K,which holds it
in a translationally inactive state, and that Ang1 stimulates Src interaction with hnRNP-K, phosphorylation of the
RNA-binding protein, release of these transcripts and upregulation of UCP2 protein expression. This study demon-
strates a newmechanism for post-transcriptional regulation of UCP2 by the vascular protective ligand Ang1. The
ability to rapidly upregulate UCP2 protein expression may be important in protecting endothelial cells from
excessive generation of potentially damaging reactive oxygen species.
© 2014 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license
Open access under CC BY-NC-ND license.
(http://creativecommons.org/licenses/by/3.0/).1. Introduction
Angiopoietin-1 (Ang1) is a secreted ligand essential for develop-
ment of the vascular system as well as maintenance and protection of
the mature vasculature [1,2]. This ligand is a glycoprotein of approxi-
mately 70 kDa [3] and, together with angiopoietins 2, -3 and -4, is a
member of the angiopoietin family of proteins [1,2]. In development
Ang1 is required for the latter stages of blood vessel formation, where
it acts to regulate branching and interaction of endothelial cells in
nascent vessels with extracellular matrix and perivascular support
cells [4,5]. Post-development effects of Ang1 are broadly protective
and the ligand has been shown to inhibit microvessel regression,
suppress vascular inﬂammation and inhibit vessel leakage [1,2,6]. The
protective effects of Ang1 are important in maintaining a quiescentept of Cardiovascular Sciences,
aster Road, Leicester LE1 9HN,
ment of Health Sciences, Bevan
. This is an open access article underand stable vasculature [1]. At the cellular level Ang1 acts to suppress
apoptosis, enhance migration, promote monolayer integrity and inhibit
inﬂammatory gene expression in endothelial cells [1,2,6].
The primary receptor for Ang1, and the other angiopoietins, is the
receptor tyrosine kinase Tie2 [3]. Binding of Ang1 to Tie2 results in
phosphorylation and activation of the receptor and stimulation of
downstream signalling cascades including the phosphatidylinositol-3-
kinase pathway [7]. This pathway has key roles in the anti-apoptotic ac-
tions of Ang1 [8,9]. Phosphatidylinositol-3-kinase also contributes to
Ang1 suppression of endothelial inﬂammation [10], as does ABIN2, an
intermediate that is recruited to activated Tie2 and acts as an inhibitor
of the inﬂammatory transcription factor NFkB [11,12]. Another signal-
ling intermediate involved in Ang1 action is the protein Dok-2 [13].
This adaptor protein is recruited to the activated receptor where it
gets phosphorylated leading to binding of Nck and p21-activating
kinases that are involved in Ang1 activated endothelial migration [14].
Although a number of signalling pathways have been implicated in
mediating Ang1 actions, our understanding of how this ligand regulates
cellular function is still comparatively poor. In particular we know
relatively little about the pathways involved in the cellular protective
effects of Ang1. In order to uncover signalling components mediatingthe CC BY license (http://creativecommons.org/licenses/by/3.0/).
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proteins that become tyrosine phosphorylated in response to Ang1 in
endothelial cells. Here we report the RNA-binding protein heteroge-
neous nuclear ribonucleoprotein-K (hnRNP-K) as a new intermediate
in Ang1 signalling involved in post-transcriptional control of the
antioxidant mitochondrial uncoupling protein-2.
2. Materials and methods
2.1. Materials
Recombinant human Angiopoietin1 was purchased from R&D
Systems and used at a concentration of 2.8 nM (monomer). UCP2
antibodies were from Biolegend, and hnRNP-K antibodies were
from Abcam. All other reagents were as previously detailed [11].
hnRNP-K cDNA was a kind gift from Professor Sui Huang (North-
western University Medical School, Chicago, IL, USA).
2.2. Cell culture
Human umbilical vein endothelial cells (HUVEC) were purchased
from Promocell and maintained in medium 199 supplemented with
20% fetal calf serum (FCS), heparin 5 units/ml and endothelial cell
growth supplement (50 μg/ml). Only passages 3–5 were used in exper-
iments. The EA.hy.926 endothelial cell line [15] was a generous gift
from C. J. Edgell (University of North Carolina) and were maintained
Dulbecco's modiﬁed Eagle's medium supplemented with 10% FCS.
Chinese Hamster Ovary (CHO) cells were maintained in minimum
essential media supplemented with 10% FCS. All cells were cultured at
37 °C in a humid atmosphere containing 5% CO2 in air. For transfection,
80% conﬂuent cells were transfected with plasmid DNA using lipofecta-
mine 2000 according tomanufacturer's protocol. Cells were cultured for
18 h post-transfection before lysis.
2.3. Immunoprecipitation and Immunoblotting
Before lysis cells were washed with PBS then lysis buffer (100 mM
KCl, 5 mMMgCl2, 10 mM HEPES pH 7.0, and 0.5% Nonidet P-40 deter-
gent, 1 mM DTT, protease inhibitor cocktail) added. The cells were
scraped and the lysate centrifuged at 10,000 g for 10min at 4 °C. For im-
munoprecipitation, relevant antibodies were added to the supernatants
and incubated at 4 °C on a roller for 3 h afterwhich protein-A sepharose
was added and left for a further 3 h on the roller at 4 °C. The immuno-
precipitate was centrifuged at 3000 g for 1 min and washed in lysis
buffer 3 times. Proteins were eluted by the addition of Laemmli sample
buffer containing 100 mM dithiothreitol and heated to 95 °C for 5 min
before being resolved by SDS–PAGE. For the analysis of whole cell
protein extracts, lysates were mixed with Laemmli buffer as above.
Proteins were transferred to nitrocellulose membranes, probed with
the relevant antibodies and visualized with peroxidase-conjugated
secondary antibodies and chemiluminescent detection. Optical densities
of bands on immunoblots were quantiﬁed using ImageJ software.
2.4. RNA co-immunoprecipitation
RNA was isolated from immunoprecipitates using the protocol of
Tenenbaum [16] with a few modiﬁcations. Cells were lysed directly in
lysis buffer (100 mM KCl, 5 mM MgCl2, 10 mM HEPES pH 7.6, and
0.5% Nonidet P-40 detergent, 1 mM DTT, 100 U/ml SuperaseIn RNase
inhibitor and protease inhibitor cocktail). Cells were scraped and centri-
fuged at 14,000 g for 10 min at 4 °C. The supernatant was removed and
re-centrifuged at 14,000 g for 10 min at 4 °C. Antibodies were allowed
to bind to protein-A beads for 2 h at 4 °C in NT2 buffer (50 mM Tris
pH 7.4, 150mMNaCl, 1 mMMgCl2, 0.05% Nonidet P-40 before addition
to the supernatant. The supernatant was added to antibody coated
protein-A beads with the addition of 0.75 ml NT2 buffer, 1 mM DTT,15 mM EDTA and an extra 100 U/ml of RNase inhibitor. The immuno-
precipitation was allowed to proceed for 3 h at room temperature
with agitation after which immunoprecipitates were centrifuged at
3000 g for 20 s. The beads were washed in NT2 buffer 3 times. The
beads were then resuspended in NT2 buffer with the addition of 0.1%
SDS and 30 μg of proteinase K and incubated at 55 °C for 30 min.
Immunoprecipitated RNA was isolated using phenol:chloroform:
isoamyl alcohol extraction and ethanol precipitation.
2.5. PCR
Isolated RNA was reverse transcribed using RETROscript (Ambion)
and random decamer primers. The cDNA was used as template for
subsequent PCR to screen for the presence of UCP2 using the primers
UCP2 forward (5′ATGGTTGGGTTCAAGGCCACAGAT3′) and UCP2 re-
verse (5′CATGCTCAGAGCCCTTGGTGTAGA3′).
2.6. Subcloning, expression and puriﬁcation of hnRNP-K
Full-length human hnRNP-K was cloned into the Escherichia coli
expression vector pLEICS-01 (University of Leicester) encoding an N-
terminus His6-tag using the primers; forward 5′TACTTCCAATCCATGG
AAACTGAACAGCCAGAAGAAACCT3′ and reverse 5′TATCCACCTTTACT
GTCATTAGAATCCTTCAACATCTGCA3′.
BL21 (Novagen) were transformed with hnRNP-K expression vector
using themanufacturer's instructions. Transformed E. coliwas grown in
Luria-Bertani broth at 37 °C, 250 rpm to an optical density of 0.6
(600 nm) after which cells were induced for expression of hnRNP-K
using Isopropyl β-D-1-thiogalactopyranoside at 1 mM at 25 °C,
250 rpm for 4 h. Cells were harvested and lysed using 10ml of lysis buff-
er (50 mM Tris pH8.0, 150 mM NaCl, 5% glycerol, 10 mM imidazole
pH 8.0, protease inhibitor cocktail fromRoche). The cells were sonicated
in the lysis buffer. The debris was pelleted at 15,000 g at 4 °C for 30min.
The supernatant was incubated with 1 ml of nickel beads (Ni-NTA
superﬂow from Qiagen) for 16 at 4 °C under gentle rocking. The beads
were then gently transferred to a 10 ml polypropylene column. The
beads were washed with 10 column volumes of wash buffer (2 M
NaCl, 20 mM Tris pH 6.8, 60 mM imidazole and 1% triton). hnRNP-K
protein was eluted using 5ml elution buffer (1M imidazole 5% glycerol,
pH 8.0). The hnRNP-K protein was dialysed against phosphate buffered
saline. The purity and concentration were analysed using coomassie
stained gels and absorbance at 280 nm respectively.
2.7. Site-directed mutagenesis
Tyrosine 458 of hnRNP-K was mutated to phenylalanine using
the primers; forward 5′CAGTGTGAAGCAGTTTGCAGATGTTGAAG3′ and
reverse 5′CTTCAACATCTGCAAACTGCTTCACACTG3′. Mutations were
introduced using Quick-Change mutagenesis (Agilent Technologies).
2.8. In vitro transcription and biotinylation of UCP2 RNA
1 μg of plasmid containing full length UCP2 with 5′ and 3′ UTR’s (1–
1647 nt) was linearized with Eco RV. The linearized plasmid was puri-
ﬁed using acetate/ethanol precipitation. UCP2 was in vitro transcribed
using MAXIscript in vitro transcription kit (Ambion). Transcription
was conﬁrmed by gel electrophoresis and concentration was deter-
mined using an absorbance at 260 nm. The in vitro transcribed RNA
was biotinylated using the Pierce RNA 3′-biotinylation kit from Thermo
Scientiﬁc according to the manufacturer's instructions.
2.9. Src-mediated phosphorylation of hnRNP-K
Puriﬁed hnRNP-K was phosphorylated by activated Src (Sigma).
Brieﬂy, 500 ng of puriﬁed hnRNP-K was incubated with 1 ng of active
src in kinase assay buffer (5 mM MOPS, pH 7.2, 2.5 mM glycerol 2-
Fig. 1. Ang1 activates phosphorylation of hnRNP-K and interaction with Src. Endothelial
cells were challenged with Ang1 for 30 min. Lysates were immunoprecipitated with anti-
phosphotyrosine. Immunoprecipitates (PY) and whole cell lysates (Wcl) were probed for
hnRNP-K by immunoblotting. A, HUVEC and B, EA.hy926. C, hnRNP-K immunoprecipitated
from EA.hy926 with anti-phosphotyrosine was quantiﬁed by densitometric scanning of
blots. Data are means relative to control-treated cells (p b 0.05, Student's ‘t’ test). D, Time
course of hnRNP-K phosphorylation in EA.hy926. E, EA.hy926 cells were stimulated with
Ang1 for 10 min before lysis and immunoprecipitation of hnRNP-K. Immunoprecipitates
were probed for co-immunoprecipitating Src as indicated.
Fig. 2. Ang1 stimulates release of UCP2 mRNA from hnRNP-K. A, EA.hy926 cell lysates were
immunoprecipitated with non-speciﬁc antibody or anti-hnRNP-K and bound UCP2 mRNA
detected by RT/PCR. B, Cells were treated with Ang1 for the times indicated. hnRNP-K was
immunoprecipitated and UCP2 mRNA bound to hnRNP-K was detected by RT/PCR. C,
UCP2 mRNA co-immunoprecipitated with hnRNP-K was quantiﬁed by scanning gels from
3 independent experiments. Data were normalized to hnRNP-K immunoprecipitated
(*p b 0.05, Student's ‘t’ test).
1381T.A. Tahir et al. / Cellular Signalling 26 (2014) 1379–1384phosphate, 4 mM MgCl2, 2.5 mM MnCl2, 1 mM EGTA, 0.4 mM EDTA,
50 ng/μl BSA, 50 μM DTT and 0.26 mM ATP) for 15 min at 30 °C.
2.10. UCP2 mRNA binding assay
300 ng of biotinylated UCP2 RNA was incubated with 500 ng of pu-
riﬁed Src-phosphorylated or non-phosphorylated hnRNP-K in binding
buffer (50 mM NaCl, 10 mM HEPES pH8.0, 0.1 mM EDTA and 1 mM
EDTA) for 30min in a volume of 30 μl at room temperature. The volume
was then increased to 500 μl using binding buffer. Streptavidin beads
were added to the mixture and incubated for 1 h on a roller at 4 °C.
The beads were washed using binding buffer supplemented with
0.01% triton. Proteins were eluted using sample buffer and loaded
onto a 7.5% gel and transferred onto a nitrocellulose membrane.
Proteins were visualized using chemiluminescence.
2.11. Reactive oxygen species
ROS was detected in cells using the ﬂuorescent marker dichlor-
ﬂuorescein. Brieﬂy, cells were placed in serum-free medium and
activated with 100 ng/ml TNFα for 30 min with or without a 10 min
preincubation of Ang1. Media was then replaced with serum-free media
lacking phenol red and containing 10 μM 2′7′-dichlorﬂuorescein-
diacetate (DCFH-DA) and incubated for 15 min. After washing twice
with serum-free media lacking phenol red, ﬂuorescence and phase
contrast microscopy was used to image cells. For quantiﬁcation the
fraction of ﬂuorescent cells counted in 5 ﬁelds for each treatment in
each experiment was recorded.
3. Results
The signal transduction pathways mediating the actions of Ang1 in
endothelial cells are incompletely deﬁned. To identify novel signalling in-
termediates involved in Ang1 actionwe performed anti-phosphotyrosine
immunoprecipitations from endothelial cells treated with control vehicle
or Ang1 and identiﬁed recovered proteins by mass spectrometry (data
not shown). A protein consistently increased in the phosphotyrosine-
containing fraction from Ang1-treated cells was the RNA binding protein
hnRNP-K, suggesting that Ang1 can activate hnRNP-K phosphorylation.
To conﬁrm this directly, HUVEC were stimulated with Ang1 and
anti-phosphotyrosine immunoprecipitates from these cells probed
by immunoblotting with anti-hnRNP-K antibodies. This revealed
increased hnRNP-K in the immunoprecipitates following Ang1 treat-
ment (Fig. 1A). Similar results were obtained with the endothelial
line EA.hy926 (Fig. 1B, C). Activation of phosphorylation occurred
within 10 min of ligand addition (Fig. 1D). We note that hnRNP-K
was among a group of proteins recently reported by others to become
tyrosine phosphorylated in response to Ang1 [17].
The best-characterized mechanism for tyrosine phosphorylation
of hnRNP-K is that mediated by Src. This tyrosine kinase can directly
bind to hnRNP-K [18] leading to phosphorylation on a number of
tyrosine residues in the RNA binding protein [19,20]. We were inter-
ested therefore to test whether Ang1 affects interaction of Src with
hnRNP-K. Endothelial cells were activatedwith Ang1, hnRNP-K immuno-
precipitated and immunoprecipitates probed for the presence of Src by
immunoblotting. As shown in Fig. 1E, Ang1 stimulated Src interaction
with hnRNP-K.
hnRNP-K can bind to speciﬁc mRNA species, including transcripts
encoding the mitochondrial protein UCP2 [21]. In order to determine
the potential functional signiﬁcance of Ang1-induced hnRNP-K
phosphorylation we tested the effect of the ligand on the ability of
hnRNP-K to bind UCP2 mRNA. hnRNP-K was immunoprecipitated
from cell lysates and probed for bound UCP2 mRNA. UCP2 mRNA
was found bound to hnRNP-K in endothelial cells under basal condi-
tions (Fig. 2A). The effect of Ang1 on this was examined by stimulat-
ing cells with the ligand, lysing cells, immunoprecipitating hnRNP-K
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rapid decrease in UCP2 mRNA bound to hnRNP-K (Fig. 2B). Similar
to activation of hnRNP-K phosphorylation, Ang1 activated UCP2
mRNA dissociation from hnRNP-K within 10 min (Fig. 2B,C).
To examine further the interaction of UCP2 mRNA and hnRNP-K we
expressed human hnRNP-K in E. coli and performed in vitro binding
assays with the puriﬁed protein (Fig. 3). Incubation of biotinylated
UCP2 mRNA with hnRNP-K followed by recovery of the mRNA using
streptavidin beads conﬁrmed direct binding between the transcripts
and hnRNP-K in vitro (Fig. 3B). Our ﬁnding that Ang1 activates Src inter-
action with hnRNP-K and tyrosine phosphorylation prompted us to test
the effects of Src-mediated phosphorylation of hnRNP-K onUCP2mRNA
binding in vitro. Incubation of puriﬁed hnRNP-K with Src resulted in
tyrosine phosphorylation of the RNA binding protein (Fig. 3C), consis-
tent with previous reports, and our ﬁndings in endothelial cells (Fig. 1).
Importantly, UCP2 mRNA binding to hnRNP-K was decreased following
tyrosine phosphorylation of hnRNP-K by Src (Fig. 3C). Several tyrosine
residues in hnRNP-K are known to be phosphorylated by Src [20,22].
However, one residue in particular, Y458, has been shown to be critical
for regulating binding with at least one mRNA species. Reticulocyte 15-
lipoxygenase (LOX) mRNA binds hnRNP-K via a C/U-rich region in its 3′
UTR and this binding is disrupted by Y458 phosphorylation [22,23]. To
test whether Y458 phosphorylation is also involved in suppression of
UCP2 mRNA interaction with hnRNP-K we constructed a mutant version
of hnRNP-Kwith phenylalanine in place of tyrosine at this position. Com-
parison of the effects of Src-mediated phosphorylation on UCP2 mRNA
binding between wild-type and Y458F versions of hnRNP-K revealed
that in contrast to the wild-type protein, Src did not suppress UCP2
mRNA binding to the Y458F mutant (Fig. 3C,D). These data show that,
as with LOXmRNA binding, UCP2mRNA binding to hnRNP-K is inhibited
by Y458 phosphorylation by Src.
The effects of Ang1 on UCP2 mRNA suggest that the ligand may
affect UCP2 protein levels. This was examined and Ang1 was found to
stimulate a signiﬁcant increase in UCP2 protein expression, without
increasing total cellular UCP2 mRNA (Fig. 4A–C).Fig. 3. UCP2 mRNA binds puriﬁed hnRNP-K and is regulated by Src. A, Coomassie stained gel o
puriﬁed on a nickel column. Positions of molecular massmarkers are indicated in kDa. B, Bindin
the absence of UCP2mRNA,with biotinylatedUCP2mRNA orwith biotinylated UCP2mRNA in t
mRNA was recovered with immobilized streptavidin and bound hnRNP-K detected by immun
changed to phenylalanine (Y458F) was phosphorylated by addition of Src and then tested fo
hnRNP-K and tyrosine phosphorylation of input hnRNP-K are shown as indicated. D, Binding of
Binding is normalized to that in the absence of phosphorylation for each hnRNP-K and presente
effect of phosphorylation).The ability of Ang1 to stimulate release of UCP2mRNA from hnRNP-K
and increase UCP2 protein expression without increasing cellular UCP2
mRNA levels suggests that the RNA-binding protein might act to hold
UCP2 transcripts in a translationally inactive state that is relieved by
Ang1-induced transcript release. To test whether hnRNP-K suppresses
translation of UCP2, therefore, cells were transfected with a plasmid
encoding UCP2, including the 5′ and 3′ untranslated regions, together
with a plasmid encoding GFP (control) or GFP-tagged hnRNP-K. Levels
of expression of transfected UCP2 were too low to detect when endothe-
lial cells were transfected (data not shown) so these experiments were
performed with CHO cells. As shown in Fig. 4D, cells transfected with
UCP-2 plasmid along with GFP demonstrated increased expression of
UCP2 protein as expected. However, co-transfection with hnRNP-K
decreased expression of UCP2 protein. Furthermore, cells transfected
with a plasmid encoding UCP2 showed, as expected, increased cellular
UCP2 mRNA levels but, in contrast to the effects of hnRNP-K expression
on UCP2 protein, UCP2 mRNA levels were not decreased by hnRNP-K
(Fig. 4D). These data indicate that hnRNP-K can act to suppress UCP2
translation.
UCP2 is known to affect cellular reactive oxygen species (ROS) and
the protein inhibits ROS production from the mitochondria [24,25].
Upregulation of UCP2 protein by Ang1, therefore, would be expected
to have a suppressive effect on ROS production. To gain insight into
the possible biological signiﬁcance of Ang1 regulation of UCP2 protein
we examined whether Ang1 could modify ROS production. TNF-α has
previously been reported to stimulate mitochondrial ROS production
in endothelial cells [26]. We found that TNF-α-treated endothelial
cells demonstrated increased ROS production (Fig. 5). Pre-treating
cells with Ang1 caused a signiﬁcant inhibition of TNF-α-induced Ros
production (Fig. 5).
4. Discussion
The present study identiﬁes a new mechanism by which Ang1
regulates UCP2, a mitochondrial protein important in regulating ROSf recombinant His6-tagged wild-type hnRNP-K or Y458F hnRNP-K expressed in E. coli and
g of UCP2mRNA andwild-type hnRNP-K in vitro. Recombinant hnRNP-Kwas incubated in
he presence of a ten-fold excess of non-biotinylated UCP2mRNA as indicated. Biotinylated
oblotting. C, Recombinant hnRNP-K or recombinant hnRNP-K in which tyrosine-458 was
r binding to biotinylated UCP2 mRNA as above. Blots of bound hnRNP-K as well as input
hnRNP-K to UCP2mRNAwas analysed in vitro as above and blots quantiﬁed by scanning.
d asmeans and SEM for three independent experiments (*p b 0.05, Student's ‘t’ test, for the
Fig. 4. Ang1 activates UCP2 protein expression in endothelial cells. A, EA.hy926 cells were
treated with Ang1 for the times indicated and UCP2 protein detected by immunoblotting.
B, UCP2 and GAPDHmRNAwere detected in cell lysates by RT/PCR following Ang1 activa-
tion. C, UCP2 protein was quantiﬁed by scanning blots from three independent experi-
ments. UCP2 protein levels were normalized to actin and data are presented as mean
and SE and shown relative to UCP2 in control-treated cells (*p b 0.05, Student's ‘t’ test).
D, hnRNP-K suppresses UCP2 translation. CHO cellswere transfectedwith plasmids contain-
ing nucleotides 1-1647 of UCP2 together with a plasmid encoding either hnRNP-K-GFP or
GFP as indicated. Approximately 18 h post-transfection cells were lysed and UCP2 protein
detected in cell lysates by immunoblotting. Blotswere stripped and re-probed forGFP to con-
ﬁrm expression of hnRNP-K-GFP and GFP in appropriate cell lysates. mRNA was extracted
from cell lysates and UCP2 mRNA detected by RT/PCR (15 cycles).
Fig. 5.Ang1 inhibition of ROS generation. Endothelial cellswere stimulatedwith TNFα in the
absence andpresence of Ang1 before detection of ROS usingDCFH-DA. Data are presented as
means and SE and shown relative to the fraction of ROS-positive cells in control-treated cells
(*p b 0.05, for Ang1 inhibition of TNF-activated ROS, Student's ‘t’, test n= 3).
1383T.A. Tahir et al. / Cellular Signalling 26 (2014) 1379–1384levels in cells. We ﬁnd that in endothelial cells UCP2 mRNA is bound to
the RNA binding protein hnRNP-K. Ang1 stimulates interaction of the
tyrosine kinase Src with hnRNP-K and tyrosine phosphorylation of the
RNA-binding protein. This is associated with the release of UCP2
mRNA and upregulation of UCP2 protein in the cells. This mechanism
provides a pool of UCP2 mRNA ready for translation, allowing Ang1 to
rapidly upregulate UCP2 protein without the need to activate gene ex-
pression. The increased speed afforded by such a post-transcriptional
response may be particularly important for UCP2 as this protein has a
very short half-life [27] and regulates levels of an intermediate, ROS,
whose actions can be potentially damaging to the cell.
hnRNP-K was originally identiﬁed as part of the heterogenous
ribonucleoprotein complexes involved in processing pre-mRNA [28].
The protein is localized primarily to the nucleus but is also found in
lower abundance in the cytoplasm [29–32]. hnRNP-K has roles in
control of gene expression by modulating chromatin remodeling, tran-
scriptional control and splicing, as well as transporting speciﬁc tran-
scripts into the cytosol and regulating mRNA translation by binding
transcripts [33]. The ability of hnRNP-K to regulate mRNA translation
appears to be important for control of local protein expression in cells.
This was shown recently in oligodendrocytes where hnRNP-K was
found to bind mRNA encoding myelin basic protein, holding thesetranscripts in a translationally silent state whilst transporting them to
the membrane and areas of myelination [34]. In these cells integrin
activation resulted in hnRNP-K tyrosine phosphorylation releasing the
transcripts and leading to localized increased myelin basic protein
translation [34].
The interaction of speciﬁc mRNA with hnRNP-K is regulated by
phosphorylation state of the RNA-binding protein, with increased
tyrosine phosphorylation leading to release of speciﬁc mRNAs from
the protein [20,35]. Conversely, there are instances of enhanced binding
of some transcripts in response to tyrosine phosphorylation of the
protein, for example platelet-derived growth factor enhances phos-
phorylation of hnRNP-K and its binding to mRNA encoding myosin
regulatory light-chain interacting protein [36]. This suggests that tyro-
sine phosphorylation-dependent regulation of hnRNP-K interaction
with transcripts is complex, transcript speciﬁc and is likely to involve
other proteins.
The best-described example of signal-regulated mRNA interaction
involving phosphorylation of hnRNP-K is in the control of reticulocyte
LOX. Expression of LOX protein is suppressed in immature erythroid
cells by binding of LOX mRNA to hnRNP-K which prevents its transla-
tion [37]. Phosphorylation of hnRNP-K via Src causes release of LOX
mRNA and upregulation of LOX protein [20]. LOX mRNA binding to
hnRNP-K is mediated by C/U rich elements in the 3’ untranslated region
[23]. Similar elements are present in the 3′ region of UCP2 mRNA. This,
together with our ﬁnding that, like LOX mRNA, UCP2 mRNA binding to
hnRNP-K is sensitive to phosphorylation status of Y458, suggests that
both mRNA species may share a similar mechanism of phosphorylation-
induced release. hnRNP-K contains 17 potential tyrosine phosphorylation
sites and it is likely that different agonists activate phosphorylation of
different tyrosines leading to different effects on mRNA binding. Indeed,
insulin has been reported to stimulate tyrosine phosphorylation of
hnRNP-K and, in an insulin receptor overexpressing cell line, this
increased UCP2 mRNA binding [21]. The mechanisms responsible
1384 T.A. Tahir et al. / Cellular Signalling 26 (2014) 1379–1384for the differing effects of Ang1 and insulin on hnRNP-K:mRNA binding
are not known but may reﬂect differences in phosphorylation sites
stimulated by the two ligands and/or differences between cell types.
Uncoupling protein-2 is a 33 kDa anion carrier found in the
mitochondrial inner membrane [38]. The protein is important for
control of mitochondrial membrane potential [39] and generation of
reactive oxygen species [40]. Increased UCP2 is associated with partial
depolarization of the mitochondrial membrane and suppression of
mitochondrial ROS production [25]. UCP2 mRNA levels in tissues have
been reported as generally highwhereas protein levels are low, suggest-
ing that translation of the protein is tightly controlled [41]. Consistent
with this, starvation and lipopolysaccharide induce substantial changes
in UCP2 protein levels in vivo without accompanying effects on mRNA
levels [41]. It has also been reported that UCP2 protein has a short
half-life of around 30 min [27]. Translational control of UCP2, together
with the short half-life of the protein, may be important for allowing
rapid responses in intracellular UCP2 protein levels to cellular stimuli.
A key function of UCP2 to emerge in recent years is its ability to
suppress mitochondrial generation of ROS [24,25]. Elevated ROS can
have detrimental effects on cells and tissues, for example increased
ROS has been associatedwith enhanced expression of endothelial adhe-
sion molecules and endothelial apoptosis as well as vascular dysfunc-
tion and increased atherosclerosis [42,43]. Furthermore mitochondrial
DNA is a critical target for oxidative damage because of their proximity
to electron chain and the crucial roles played by mitochondrial DNA
products. It is clearly important therefore that levels of ROS are tightly
controlled. UCP2 has been shown to protect endothelial cells via its abil-
ity to inhibit mitochondrial ROS generation, with increased expression
of UCP2 protein inhibiting ROS-mediated apoptosis in endothelium
[25]. Overexpression of UCP2 also suppresses endothelial NFkB activa-
tion and enhances vascular relaxation [25]. Consistent with a protective
role of UCP2 in the vasculature, transgenic low density lipoprotein
receptor deﬁcient mice lacking UCP2 in circulating cells exhibit in-
creased atherosclerosis [44]. Similarly, UCP2-deﬁcient mice display
elevated atherosclerosis, decreased endothelial nitric oxide levels and
increased vascular adhesion molecule expression [45] as well as
increased salt-induced hypertensive changes [46]. Thus UCP2 appears
to have a broadly protective effect in endothelium and the vasculature.
Ang1 is also known to have vascular protective effects and suppresses
inﬂammatory gene expression in endothelial cells and blocks
microvessel regression, vascular leakage and inﬂammation in vivo [6].
Induction of UCP2 protein by Ang1 therefore could be considered an
additional protective effect of Ang1, to limit ROS levels in endothelium.
In conclusion, our data shows that Ang1 activates tyrosine phos-
phorylation of hnRNP-K, release of UCP2 mRNA from the RNA-binding
protein and increasing UCP2 protein levels in the cells. This increase in
UCP2 is likely to be important in preventing excess ROS production.
Signiﬁcantly, this post-transcriptional control mechanism will allow
rapid responses to the ligand.
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